Clinical Trial Results:
            A Phase-3 Randomized, Double-Blind, Efficacy and Safety Study Evaluating the Fixed Dose Combinations of TAK-491 Plus Chlorthalidone (40/12.5 mg and 40/25 mg) in Subjects With Grades 2 or 3 Essential Hypertension, Who Do Not Achieve Target Blood Pressure Following Treatment With TAK-491 40mg Monotherapy
    
| 
                 Summary 
         | 
        |
    EudraCT number  | 
        2011-000220-16 | 
    Trial protocol  | 
        EE NL DE SK SE ES GB PL LT HU IT | 
    Global completion date  | 
        
                                    27 Dec 2012
                             
         | 
    
| 
                 Paediatric regulatory details 
         | 
        |
    Is the trial part of an agreed EMA paediatric investigation plan?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 45 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 46 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
| 
                 Results information 
         | 
        |
    Results version number  | 
        v1(current) | 
    This version publication date  | 
        
                                    20 May 2016
                             
         | 
    
    First version publication date  | 
        
                                    20 May 2016
                             
         | 
    
    Other versions  | 
        |
    Summary report(s)  | 
                                2011-000220-16 Results | 
    
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.